Cleveland Clinic lists bioidentical hormone therapy among the concerns addressed by its specialized women’s health service. The word may sound like a complete description of a medicine, yet it does not provide the formulation details needed to assess a particular progesterone prescription.
Reviewed September 29, 2026, this assessment follows the difference between that service description and a product record. It does not claim that Cleveland supplies a named micronized capsule, manufactures hormones or uses one standard preparation for every patient. The focus is what the published word can establish without acquiring properties it does not describe.
Read this article by section
The term appears within a clinical service, not a checkout
The specialized women’s health page identifies bioidentical therapy as part of the center’s work. That supports reviewing Cleveland as a relevant clinical service. It does not establish a retail product, a routine formulation or a manufacturer associated with every consultation.
A reader should therefore treat the word as a subject for discussion, not as a completed order description. The Mayo Clinic review considers a comparable term listed among consultation questions. The distinction between discussing a medicine category and confirming its supply is essential to a fair comparison. More expansive institutional language does not make the product record more specific or demonstrate better clinical results.
Chemical identity is not a claim that no manufacturing occurred
The exact Prometrium label describes progesterone synthesized from plant-source starting material and chemically identical to ovarian progesterone. This is an identified oral product reference, not evidence that Cleveland prescribes it. The description shows why the origin of a starting material and the identity of the resulting hormone are different facts.
It also prevents “natural” from becoming shorthand for an untouched substance or a guarantee about the whole capsule. Our bioidentical approval guide addresses that distinction. Cleveland’s single service term cannot supply a manufacturing history, establish a finished product’s approval or determine whether its formulation fits an individual’s medical circumstances.
Compounded and bioidentical are not interchangeable categories
The FDA compounding record explains that compounded drugs do not undergo its premarket approval process. Cleveland’s use of bioidentical terminology does not establish that a future medicine will be compounded. Nor would the same word make a compounded preparation FDA-approved.
The useful question is which exact preparation the clinician is considering and what regulatory status applies to it. Utah’s review examines institutional wording that explicitly distinguishes conventional and compounded options. These are information differences, not findings that one institution necessarily prescribes a safer product. No pharmacy inspection, product assay or dispensing transaction has been conducted for this assessment.
The active hormone does not supply the inactive ingredient list
Prometrium’s specific DailyMed record lists peanut oil and gelatin among its inactive ingredients and includes a peanut-allergy contraindication. Those facts belong to that product. They are not attributed to an unidentified Cleveland prescription or to every medicine described as bioidentical.
This is why the eventual label matters even after the hormone’s name is known. The micronized meaning guide also separates a formulation descriptor from the complete medicine record. A reader should not deduce an allergy conclusion from a particle-size term, plant origin or provider category. This review supplies no replacement product or route substitution; formulation and clinical questions need the professionals responsible for the actual prescription.
A generic description should not be confused with compounding
The FDA generic-drug explanation sets out requirements concerning the active ingredient, strength, dosage form, route and bioequivalence for approved generics. That is a distinct regulatory pathway. An unnamed product on a clinic page cannot be classified as an approved generic merely because it shares a hormone name with a branded medicine.
Cleveland’s public service record does not identify a particular generic manufacturer. It also does not confirm the complete formulation a pharmacy would dispense. The progesterone and progestin words guide considers an earlier identity question: whether the terms even refer to the same active substance. Each comparison needs the relevant evidence instead of allowing one familiar label to stand for all the others.
The appointment format does not finish the product discussion
Cleveland’s menopause treatment page describes shared virtual appointments and separate individual follow-up where medication or testing is needed. It also refers to services in Ohio, Florida and London. Those access details remain specific to the pathway, rather than proving an unrestricted medicine offer.
A prospective patient still needs to establish which appointment is relevant and what it costs. The separate CustomFit description is not used as a progesterone price. No complete consultation, medicine and continuing-care total is verified here. The ability to join a discussion or attend a health assessment does not, by itself, establish a prescription, a selected pharmacy product or personal treatment suitability.
What a precise comparison can reasonably conclude
The center’s published information verifies that relevant hormone questions fall within its clinical work. The medicine remains unidentified until the proposal names more than the broad category. That limit does not negate the service; it defines what a document-based review can say about it.
A useful comparison would retain the same level of precision for every provider: whether the evidence concerns a service, a particular approved product or a preparation whose details remain unresolved. This assessment provides no clinical ranking and reports no firsthand appointment. Its conclusion is that Cleveland offers a relevant consultation setting, while chemical identity, manufacturing, excipients and product-specific evidence must still be established for the actual medicine under discussion.
Documents behind the details
Read the source for the product, use and context it actually describes. A source type is not a rating of a provider.
- Cleveland Clinic — Specialized Women’s Health and MenopauseOfficial health-system clinical service, appointment or location page; exact product, personal access and full cost remain unconfirmed. · Checked 2026-09-29
- DailyMed — PROMETRIUM progesterone capsule, Acertis Pharmaceuticals LLCExact identified oral product labeling, updated July 23, 2026; text only, no package-image inspection. Ingredient, formulation and WHI study details are not assigned to a health-system prescription. · Checked 2026-09-29
- FDA — Understanding the Risks of Compounded DrugsFederal primary explanation of absent FDA approval and premarket review, with risk-based oversight; not a claim that compounding is wholly unregulated or that any clinic uses it. · Checked 2026-09-29
- FDA — Generic Drug FactsFederal primary requirements for approved generic drugs; not compounding evidence or confirmation that all inactive ingredients match. · Checked 2026-09-29
- Cleveland Clinic — Menopause TreatmentOfficial health-system clinical service, appointment or location page; exact product, personal access and full cost remain unconfirmed. · Checked 2026-09-29